- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03477331
Antithrombotics' Therapeutic Optimization in Hospitalized Patients Using Physiologically- and Population-based Pharmacokinetic Modeling (OptimAT)
April 8, 2024 updated by: Jean-Luc Reny, University Hospital, Geneva
The main goal of the OptimAT study main goal is to validate a PBPK model for 3 direct oral anticoagulants (rivaroxaban, apixaban, dabigatran) and 3 P2Y12 inhibitors (clopidogrel, ticagrelor, prasugrel) in hospitalized patients.
Study Overview
Status
Completed
Conditions
Detailed Description
Patients treated with antithrombotics are at risk of both severe ischemic and bleeding events.
However, current clinical scores are insufficiently discriminant to predict the most favorable drug and dosing for an improved net clinical benefit.
Physiologically and population-based pharmacokinetic models (PBPK and POPPK respectively) incorporate substrate specific properties obtained from experimental in-vitro experiments as well as patients' demographic, genetic and physiological in vivo data in order to characterize the dose-concentration relationships.
As such, they can be used to simulate and predict PK profiles accounting for specific patients' characteristics and are the basis of dosing optimization.
These models could be a valuable tool to predict antithrombotic blood concentration in a given patient.
Our main goal is to elaborate predictive models characterizing the dose-concentration relationship with influencing variables of three direct oral anticoagulants (DOAC) (rivaroxaban, apixaban, dabigatran) and three P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) in hospitalized patients, which will serve as basis for drug selection and dosage optimization.
Study Type
Observational
Enrollment (Actual)
444
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
GE
-
Genève, GE, Switzerland, 1205
- Hopitaux universitaires de Genève, 4 rue Gabrielle-Perret-Gentil
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
Hospitalized patients
Description
Inclusion Criteria:
- Hospitalized patients at any of the Geneva University Hospitals 18 yo and older
- Treated with DOAC (dabigatran, rivaroxaban, apixaban) or/and P2Y12 (clopidogrel, ticragrelor et prasugel) at the time of study blood sampling
- Understanding of French language and able to give an inform consent.
Exclusion Criteria:
- Patients with a reduced life span (<6 mois)
- Exclusion criteria during follow up
- Change in dosage or cessation of the DOAC or P2Y12 taken by the participant follow up data will be censored at the time of change.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Area Under the Curve (AUC)
Time Frame: 2 years
|
Difference between observed and PBPK model-predicted AUC (mean prediction error)
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Trough Concentration (Cmin)
Time Frame: 2 years
|
Difference between observed and PBPK model-predicted Cmin (mean prediction error)
|
2 years
|
|
Area Under the Curve (AUC) (stability of the model over time)
Time Frame: 2 years
|
Difference between observed and model-predicted AUC during patients' rehospitalization (stability of the model over time)
|
2 years
|
|
Major bleeding event-free survival
Time Frame: 2 years
|
Major bleeding event-free survival according to drug exposure (AUC) during a prospective during a follow-up of two years for DOACs (dabigatran, rivaroxaban, apixaban) and P2Y12 receptor inhibitors (clopidogrel, ticragrelor, prasugel)
|
2 years
|
|
Peak concentration (Cmax)
Time Frame: 2 years
|
Difference between observed and PBPK model-predicted Cmax (mean prediction error)
|
2 years
|
|
Thrombosis event-free survival
Time Frame: 2 years
|
Thrombosis event-free survival according to drug exposure (AUC) during a prospective during a follow-up of two years for DOACs (dabigatran, rivaroxaban, apixaban) and P2Y12 receptor inhibitors (clopidogrel, ticragrelor, prasugel)
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jean-Luc Reny, Prof, Hopitaux Universitaires de Geneve
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Terrier J, Gaspar F, Gosselin P, Raboud O, Lenoir C, Rollason V, Csajka C, Samer C, Fontana P, Daali Y, Reny JL; OptimAT study group. Apixaban and rivaroxaban's physiologically-based pharmacokinetic model validation in hospitalized patients: A first step for larger use of a priori modeling approach at bed side. CPT Pharmacometrics Syst Pharmacol. 2023 Dec;12(12):1872-1883. doi: 10.1002/psp4.13036. Epub 2023 Oct 4.
- Gaspar F, Terrier J, Favre S, Gosselin P, Fontana P, Daali Y, Lenoir C, Samer CF, Rollason V, Reny JL, Csajka C, Guidi M. Population pharmacokinetics of apixaban in a real-life hospitalized population from the OptimAT study. CPT Pharmacometrics Syst Pharmacol. 2023 Oct;12(10):1541-1552. doi: 10.1002/psp4.13032. Epub 2023 Sep 18.
- Achour B, Gosselin P, Terrier J, Gloor Y, Al-Majdoub ZM, Polasek TM, Daali Y, Rostami-Hodjegan A, Reny JL. Liquid Biopsy for Patient Characterization in Cardiovascular Disease: Verification against Markers of Cytochrome P450 and P-Glycoprotein Activities. Clin Pharmacol Ther. 2022 Jun;111(6):1268-1277. doi: 10.1002/cpt.2576. Epub 2022 Mar 28.
Helpful Links
- Apixaban and rivaroxaban's physiologically-based pharmacokinetic model validation in hospitalized patients: A first step for larger use of a priori modeling approach at bed side
- Population pharmacokinetics of apixaban in a real-life hospitalized population from the OptimAT study
- Liquid Biopsy for Patient Characterization in Cardiovascular Disease: Verification against Markers of Cytochrome P450 and P-Glycoprotein Activities
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 14, 2018
Primary Completion (Actual)
January 31, 2024
Study Completion (Actual)
January 31, 2024
Study Registration Dates
First Submitted
February 2, 2018
First Submitted That Met QC Criteria
March 23, 2018
First Posted (Actual)
March 26, 2018
Study Record Updates
Last Update Posted (Actual)
April 10, 2024
Last Update Submitted That Met QC Criteria
April 8, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017-00225
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.